{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25891233", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25891233, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with likelihood of abstinence when treated with nicotine in people with Tobacco Use Disorder as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no evidence of association between the rs1051730 genotype (allele A vs. allele G) and the likelihood of abstinence at both 7 days and 28 days after the quit attempt."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051730 and nicotine in Other:Tobacco Use Disorder (PMID 25891233), what OR was reported?", "answer": "0.89", "response": "The study reported an odds ratio (OR) of 1.10 for the association between rs1051730 and the likelihood of abstinence at 7 days, and an OR of 0.89 at 28 days."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False. The confidence intervals for both reported odds ratios (1.10 with 95% CIs 0.81 to 1.51 at 7 days, and 0.89 with 95% CIs 0.68 to 1.16 at 28 days) include the null value of 1.0."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22328925", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22328925, is the following pharmacogenomic claim supported or contradicted: Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AA + AC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that haplotypes carrying major alleles at IL28B, including the CC genotype of rs12979860, are associated with a higher likelihood of achieving a sustained virological response (SVR) to peginterferon alfa-2b and ribavirin therapy in HCV/HIV-1 coinfected patients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4803217 and peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection, Disease:HIV infectious disease (PMID 22328925), what p-value was reported for this association?", "answer": "= 0.000013", "response": "The p-value reported for the association of rs4803217 with sustained virological response (SVR) to peginterferon alfa-2b and ribavirin therapy in the study is 1.3\u00d710^\u22125."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24447405", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24447405, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with likelihood of cessation of nicotine in men with Tobacco Use Disorder as compared to allele A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no significant association between the OPRM1 allele G (rs1799971) and smoking behaviors, including cessation of nicotine in men with Tobacco Use Disorder."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs2036657 and nicotine in Other:Tobacco Use Disorder (PMID 24447405)?", "answer": 146, "response": "The study did not include a control group; it only recruited 284 subjects, all of whom were current or ex-smokers with tobacco-related diseases. Therefore, there were no controls for the analysis of rs2036657 and nicotine in Tobacco Use Disorder."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False. Since there were no controls included in the study, it does not meet the dataset minimum of N \u2265 30 for study controls."}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "30914949", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 30914949, is the following pharmacogenomic claim supported or contradicted: Genotype CT is associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study indicates that the *CYP3A4* rs2740574 A/G genotype (not CT) is associated with an increased risk of alopecia, specifically in the A/G genotype compared to the A/A genotype. There is no mention of the CT genotype being associated with increased risk of alopecia."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2740574 and bleomycin, cisplatin, etoposide in Disease:Testicular Neoplasms (PMID 30914949), what p-value was reported for this association?", "answer": "= 0.058", "response": "The reported p-value for the association of the *CYP3A4* rs2740574 A/G genotype with alopecia in testicular cancer patients was **0.047**."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "**False.** The p-value of 0.047 is greater than the alpha level of 0.01, indicating that the association would not remain significant at that threshold."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26699619", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26699619, is the following pharmacogenomic claim supported or contradicted: Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that the preferable genotype TT (rs8099917) was associated with higher rates of rapid virological response (RVR) compared to non-preferable genotypes (GG + GT)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Chronic hepatitis C virus infection (PMID 26699619)?", "answer": 687, "response": "A total of 687 cases were included in the study for rs8099917 in patients with chronic hepatitis C virus infection."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32153387", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32153387, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no statistically significant association between the IL6 -6331T > C genotype and the risk of acute kidney rejection in tacrolimus-treated transplant recipients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10499563 and tacrolimus in Other:Kidney Transplantation (PMID 32153387), what confidence interval was reported?", "answer": "0.9\u20136.9", "response": "The confidence interval reported for the odds ratio of the IL6 -6331C/C genotype compared to T/T genotype was 95% confidence interval (1.7 to 25.8)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval (1.7 to 25.8) does not include the null value of 1.0."}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "37098852", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 37098852, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with clearance of tenofovir in people with HIV Infections as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study did not report any significant associations between the polymorphisms evaluated, including those that may correspond to allele A and allele G, and the clearance of tenofovir in people with HIV infections."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1800629 and tenofovir in Other:HIV infectious disease (PMID 37098852), what p-value was reported for this association?", "answer": "= 0.2", "response": "The p-value reported for the association of rs1800629 and tenofovir in the study was 0.07."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32342502", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32342502, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased likelihood of venous thromboembolism when treated with hormonal contraceptives for systemic use. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs6025 and hormonal contraceptives for systemic use in Toxicity (PMID 32342502)?", "answer": 487, "response": "A total of 1,777 controls were included in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18574025", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18574025, is the following pharmacogenomic claim supported or contradicted: CYP2C9 *2 is associated with decreased dose of warfarin. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2C9*2 and warfarin in Dosage (PMID 18574025)?", "answer": 1321, "response": "The study included 1496 cases for the analysis of CYP2C9*2 and warfarin dosage."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21743379", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21743379, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported. The study found no statistically significant association between LPV or RTV AUC or CL and the CYP3A5 A6986G polymorphism, indicating that allele A is not associated with exposure to these drugs in children with HIV infections compared to allele G."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1045642 and lopinavir, ritonavir in Other:HIV infectious disease (PMID 21743379)?", "answer": 50, "response": "The study included 50 cases (children) for the analysis of rs1045642 and its association with lopinavir and ritonavir in HIV-infected individuals."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000010", "chain_family": "B_claim\u2192presence_absence", "pmid": "40442974", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40442974, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 40442974, rs11664064 is associated with Dosage, Toxicity outcomes for azathioprine, mercaptopurine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 40442974 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 40442974 reports quantitative statistics for the claim regarding rs11664064. Specifically, it provides an odds ratio (OR) of 3.61 (p = 1.96E-8) for the BioVU cohort and an OR of 2.42 (p = 0.039) for the All of Us cohort."}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25350695", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25350695, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **supported**. The paper identifies the SNP rs10455872 in the LPA gene, where the minor allele G is associated with a smaller LDL-C reduction in response to statin treatment compared to the major allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10455872 and HMG-CoA reductase inhibitors in Efficacy (PMID 25350695)?", "answer": 18075, "response": "The study included a total of 31,056 cases for the SNP rs10455872 (LPA) in the context of HMG-CoA reductase inhibitors' efficacy, as indicated in the combined analysis results."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "19901119", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 19901119, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that SNP rs4149081 (allele G) was associated with increased gastrointestinal (GI) toxicity during methotrexate treatment, with an odds ratio indicating a significant risk."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs4149081 and methotrexate in Disease:Acute lymphoblastic leukemia (PMID 19901119)?", "answer": 434, "response": "The study included a total of 434 cases in the discovery cohort and 206 cases in the validation cohort, making a combined total of 640 cases for the analysis of rs4149081 and methotrexate in acute lymphoblastic leukemia."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmid": "23144877", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23144877, is the following pharmacogenomic claim supported, contradicted, or not reported: Allele A is not associated with likelihood of Vomiting due to heroin in women with Pain, Postoperative as compared to allele G. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 23144877 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 23144877 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) related to the claim about allele A and its association with vomiting due to heroin in women with postoperative pain. The study specifically focuses on the association of the SNP rs540825 with fentanyl-induced emesis, not heroin."}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26715213", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26715213, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that lower risk of CNS-related adverse events was associated with the CYP2B6 983TC/CC genotype, while higher risk was associated with the CYP2B6 15582CT/TT genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs28399499 and efavirenz in Disease:HIV infectious disease (PMID 26715213), what OR was reported?", "answer": "0.3", "response": "The odds ratio (OR) reported for the CYP2B6 983TC/CC genotype in relation to CNS-related adverse events was 0.35 (95% CI 0.15\u20130.81, p = 0.015)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI 0.15\u20130.81) does not include the null value of 1.0."}]}
{"chain_id": "chain_000015", "chain_family": "B_claim\u2192presence_absence", "pmid": "24433488", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24433488, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 24433488, rs121918592 is associated with Dosage, Efficacy outcomes for desflurane, enflurane, halothane, isoflurane, sevoflurane, succinylcholine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 24433488 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 24433488 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding rs121918592 and its association with dosage or efficacy outcomes for desflurane, enflurane, halothane, isoflurane, sevoflurane, or succinylcholine."}]}
{"chain_id": "chain_000016", "chain_family": "B_claim\u2192presence_absence", "pmid": "26892777", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26892777, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26892777, SLCO1B1 low activity is associated with Metabolism/PK outcomes for atazanavir. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26892777 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 26892777 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding SLCO1B1 low activity and its association with metabolism or pharmacokinetic outcomes for atazanavir."}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23651024", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23651024, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study indicates that carriers of two C alleles (homozygotes) of the BDNF SNP rs10835210 require relatively higher methadone doses compared to heterozygotes (CT) or non-carriers (TT)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2289658 and methadone in Disease:Heroin Dependence (PMID 23651024), what OR was reported?", "answer": "1.592", "response": "The odds ratio (OR) reported for rs2289658 in relation to methadone dose was 1.592."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval for the OR (1.592) does not include the null value of 1.0."}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24123600", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24123600, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study identifies an ABCG2 haplotype (specifically the G-G haplotype) associated with higher cumulative incidence of major molecular response (CI-MMR) to imatinib, but does not support the association of allele C with increased response compared to allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2725252 and imatinib in Disease:Chronic myelogenous leukemia, BCR-ABL1 positive (PMID 24123600), what p-value was reported for this association?", "answer": "= 0.185", "response": "The p-value reported for the association of rs2725252 with imatinib response in chronic myelogenous leukemia (CML) was 0.012 in the exploratory cohort (SLEC) and 0.047 in the 400 mg/d arm of the validation cohort (SVC)."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False. The association would not remain significant at alpha = 0.01, as the reported p-values (0.012 and 0.047) are greater than 0.01."}]}
{"chain_id": "chain_000019", "chain_family": "B_claim\u2192presence_absence", "pmid": "7862671", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 7862671, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 7862671, TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34 is associated with Toxicity outcomes for mercaptopurine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 7862671 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 7862671 does not report any quantitative statistics such as p-values, odds ratios (OR), or confidence intervals (CI) for the claim regarding TPMT variants and toxicity outcomes for mercaptopurine."}]}
{"chain_id": "chain_000020", "chain_family": "B_claim\u2192presence_absence", "pmid": "29705271", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29705271, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 29705271, rs776817009 is associated with Other outcomes for o-desmethyltramadol. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 29705271 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 29705271 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs776817009 and its association with outcomes for o-desmethyltramadol."}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32606912", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32606912, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no significant association between the allele A and the dosage of sufentanil compared to allele G for the SNPs examined, including those related to IL-1A and IL-1\u03b2."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs842647 and sufentanil in Other:Pain, Postoperative (PMID 32606912), what p-value was reported for this association?", "answer": "= 0.456", "response": "The reported p-value for the association between rs842647 and sufentanil in postoperative pain was 0.456."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False. The p-value of 0.456 is not significant at alpha = 0.01."}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32451486", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32451486, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The paper identifies multiple risk variants associated with problematic alcohol use (PAU), but does not support the assertion that allele A is associated with decreased risk of alcoholism compared to allele G. The findings focus on identifying risk loci rather than protective alleles."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs2673136 and ethanol in Toxicity (PMID 32451486)?", "answer": 256395, "response": "In the study of rs2673136 and ethanol in Toxicity (PMID 32451486), there were **256,395 controls** included."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "35150001", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 35150001, is the following pharmacogenomic claim supported or contradicted: Genotype TT is not associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in people with Medulloblastoma, Glioma or Brain Neoplasms as compared to genotypes CC + CT. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **supported**. The study found no significant association between the TT genotype of CEP72 rs924607 and vincristine-induced peripheral neuropathy in the cohort of brain tumor patients, indicating that TT genotype is not associated with an increased likelihood of this condition compared to CC + CT genotypes."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "This annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs924607 and vincristine in Other:Medulloblastoma, Other:Glioma, Other:Brain Neoplasms (PMID 35150001), what confidence interval was reported?", "answer": "0.359\u201311.989", "response": "The confidence interval reported for the association of rs924607 and vincristine-induced peripheral neuropathy in the study was **[0.359\u201311.989]** for the odds ratio of 2.076, and **[1.35\u20133.43]** for the odds ratio of 2.15 in the meta-analysis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**False.** The confidence interval for the OR of 2.076 ([0.359\u201311.989]) includes the null value of 1.0, indicating that the association is not statistically significant. However, the confidence interval for the OR of 2.15 ([1.35\u20133.43]) does not include 1.0, indicating a statistically significant association in the meta-analysis."}]}
{"chain_id": "chain_000024", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is contradicted. The study found that the rs3778150-C allele is associated with an increased risk of heroin addiction, with a significant P value indicating this association."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs647303 and heroin in Toxicity (PMID 25744370), what p-value was reported for this association?", "answer": "= 0.85", "response": "The study reported a p-value of 0.85 for the association of rs647303 with heroin addiction."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29743634", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29743634, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is contradicted. The study found that allele A (rs1801394 in MTRR) is associated with a poorer response to methotrexate compared to allele G, indicating that allele A is indeed associated with response to methotrexate in patients with rheumatoid arthritis."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2847153 and methotrexate in Disease:Rheumatoid arthritis (PMID 29743634)?", "answer": 915, "response": "The study included 915 cases of rheumatoid arthritis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29415147", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29415147, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of Alcoholism due to ethanol as compared to allele A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that allele C (specifically in the context of SNP rs6990313) did not show a significant association with alcohol use disorder (AUD) compared to allele A, as the results did not survive correction for multiple comparisons."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs867858 and ethanol in Toxicity (PMID 29415147)?", "answer": 534, "response": "The study did not report any significant association for rs867858 with ethanol toxicity, and specific case numbers for this SNP were not provided in the results. Therefore, it can be inferred that the number of cases included in the analysis for rs867858 is not explicitly stated in the paper."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "False. The study does not provide a specific number of cases for rs867858, but it indicates that no significant association was found, suggesting that it likely did not meet the minimum of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24967362", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24967362, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study focuses on the MTHFR C677T (rs1801133) and ATIC T675C (rs4673993) polymorphisms, and it does not mention any association with genotypes AG + GG compared to AA. Instead, it reports that the MTHFR 677TT genotype is associated with an increased risk for nonresponse to methotrexate."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs1801133 and methotrexate in Other:Rheumatoid arthritis (PMID 24967362)?", "answer": 128, "response": "The study did not include a control group; it focused solely on 233 rheumatoid arthritis patients treated with methotrexate. Therefore, there were no controls included in the study for rs1801133."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False. The study did not include any controls, so it does not meet the dataset minimum of N \u2265 30 for study controls."}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21790903", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21790903, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study indicates that the G allele of rs6454674 is associated with an increased risk for cocaine dependence, while the C allele of rs806368 is associated with a protective effect against cocaine dependence. The specific genotypes GT + TT for rs6454674 would not be associated with increased risk compared to GG, as GG is the reference genotype for risk assessment in this context."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "This annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs6454674 and cocaine in Other (PMID 21790903)?", "answer": 492, "response": "In the study of rs6454674 and cocaine, there were **316 controls** included."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23278282", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23278282, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study indicates that patients with the ABCB1 genotype CT + TT did not show significantly increased metabolism of tacrolimus compared to those with genotype CC. In fact, the results suggest that the metabolite to parent concentration ratios were lower in patients with the CC genotype, indicating a different relationship rather than increased metabolism."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and tacrolimus in Disease:Kidney Transplantation (PMID 23278282), what p-value was reported for this association?", "answer": "< 0.024", "response": "The p-value reported for the association of rs776746 (CYP3A5 polymorphism) and tacrolimus concentrations in the study was 0.003."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True. The finding is statistically significant at alpha = 0.05, as the p-value of 0.003 is less than 0.05."}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26745506", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26745506, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9923231 and warfarin in Dosage (PMID 26745506), what p-value was reported for this association?", "answer": "< 0.0001", "response": "The p-value reported for the association of rs9923231 (VKORC1) with warfarin dosage in the study is p<0.001."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26042510", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26042510, is the following pharmacogenomic claim supported or contradicted: Genotype AA is associated with increased dose of ethanol as compared to genotype AG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs10485057 and ethanol in Dosage (PMID 26042510)?", "answer": 133, "response": "The study did not explicitly mention a separate control group for the rs10485057 polymorphism; instead, it reported genotype frequencies among alcohol consumers and non-consumers. Therefore, the number of controls specifically for the rs10485057 and ethanol dosage is not provided in the paper."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False."}]}
{"chain_id": "chain_000032", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21288825", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21288825, is the following pharmacogenomic claim supported or contradicted: Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **supported**. The study indicates that the homozygous genotype (AA) for the UGT1A1 variant is associated with a significantly higher risk of treatment discontinuation for atazanavir, while the heterozygous genotype (AG) does not show a statistically significant increase in risk compared to the GG genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "This annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and atazanavir, ritonavir in Disease:HIV infectious disease (PMID 21288825), what p-value was reported for this association?", "answer": "> 0.05", "response": "The reported p-value for the association of rs1045642 with atazanavir and ritonavir in the study is **0.105**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False. The finding is not statistically significant at alpha = 0.05, as the p-value (0.105) is greater than 0.05."}]}
{"chain_id": "chain_000033", "chain_family": "B_claim\u2192presence_absence", "pmid": "26042510", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26042510, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26042510, rs1799971 is associated with PD outcomes for nicotine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26042510 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 26042510 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs1799971 and nicotine outcomes. The study found no association between the rs1799971 polymorphism and tobacco consumption or Fagerstr\u00f6m test scores."}]}
{"chain_id": "chain_000034", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29053440", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29053440, is the following pharmacogenomic claim supported or contradicted: HLA-B *18:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is contradicted. The study found that while HLA-B *18:01* was present in some patients, it did not reach statistical significance in association with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-B*18:01 and carbamazepine in Toxicity (PMID 29053440), what OR was reported?", "answer": "8.0", "response": "The odds ratio (OR) reported for HLA-B*18:01 in the study was 3.59 (95% CI: 1.02\u201312.66), but it did not reach statistical significance (p = 0.06)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence interval for the OR (1.02\u201312.66) does not include the null value of 1.0."}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26169577", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26169577, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **contradicted**. The study identifies associations with several SNPs in the KCNIP4 gene, but the specific allele T is not mentioned as being associated with increased likelihood of cough compared to allele C. The strongest association reported is with allele A at SNP rs145489027, not T."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs7661530 and Ace Inhibitors, Plain in Other (PMID 26169577)?", "answer": 5485, "response": "In the study of rs7661530 and ACE Inhibitors in the \"Other\" group, there were 123 controls included."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "**True.** The dataset minimum of N \u2265 30 for study controls is met, as there are 123 controls."}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmid": "40413606", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40413606, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 40413606, rs28929495 is associated with Dosage, Efficacy, Toxicity, Metabolism/PK outcomes for afatinib. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 40413606 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 40413606 reports quantitative statistics, including p-values, hazard ratios (HR), and confidence intervals (CI) for various outcomes such as time-to-treatment failure (TTF) and overall survival (OS) in patients with the EGFR-G719X mutation compared to those with other uncommon EGFR mutations. For example, it states a median TTF of 19.3 months for the G719X group versus 11.2 months for others, with a hazard ratio of 0.39 (95% CI, 0.23\u20130.66; p < 0.001) for TTF. Similarly, for OS, it reports a median of 31.4 months for the G719X group versus 21.9 months for others, with a hazard ratio of 0.57 (95% CI, 0.33\u20130.98; p = 0.044)."}]}
{"chain_id": "chain_000037", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28838926", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28838926, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with decreased metabolism of clopidogrel, enalapril and sacubitril in HEK cells as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study identifies several nonsynonymous single nucleotide polymorphisms (nsSNPs) in the CES1 gene that are associated with decreased metabolism of clopidogrel, enalapril, and sacubitril in transfected HEK cells."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "functional_assay", "response": "The annotation represents a functional_assay."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201065375 and clopidogrel, enalapril, sacubitril in Metabolism/PK (PMID 28838926), what p-value was reported for this association?", "answer": "< 0.001", "response": "The study does not report a specific p-value for the association of rs201065375 with the metabolism of clopidogrel, enalapril, and sacubitril. The results indicate that this variant significantly reduced CES1 protein and/or mRNA expression levels, but no p-value is provided in the abstract or results sections for this specific association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False. Since no specific p-value is reported for the association of rs201065375 with the metabolism of clopidogrel, enalapril, and sacubitril, we cannot conclude that the finding is statistically significant at alpha = 0.05."}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24123600", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24123600, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study identifies an ABCG2 haplotype (specifically the G-G haplotype) associated with increased response to imatinib, not allele C compared to allele A."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2725252 and imatinib in Disease:Chronic myelogenous leukemia, BCR-ABL1 positive (PMID 24123600), what p-value was reported for this association?", "answer": "= 0.025", "response": "The p-value reported for the association of rs2725252 with imatinib response in chronic myelogenous leukemia (CML) was 0.012 in the exploratory cohort (SLEC) and 0.047 in the 400 mg/d arm of the validation cohort (SVC)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000039", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22951632", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22951632, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that the T allele at rs3745274 was significantly associated with virologic suppression, indicating that women with this allele had an increased likelihood of response to efavirenz and other non-nucleoside reverse transcriptase inhibitors compared to those with the GG genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3745274 and efavirenz, non-nucleoside reverse transcriptase inhibitors in Disease:HIV infectious disease (PMID 22951632), what OR was reported?", "answer": "3.61", "response": "The odds ratio (OR) reported for rs3745274 in association with virologic suppression was 3.61 (95% CI 1.16-11.22, p trend=0.03)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI 1.16-11.22) does not include the null value of 1.0."}]}
{"chain_id": "chain_000040", "chain_family": "B_claim\u2192presence_absence", "pmid": "32004414", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32004414, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 32004414, CYP2C9*9 is associated with Other outcomes for . Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 32004414 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 32004414 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding CYP2C9*9."}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23799528", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23799528, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs806377 and risperidone in Disease:Autism Spectrum Disorder (PMID 23799528), what p-value was reported for this association?", "answer": "= 0.17", "response": "The p-value reported for the association of rs806377 with risperidone in Autism Spectrum Disorder was 0.17."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000042", "chain_family": "B_claim\u2192presence_absence", "pmid": "28403410", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28403410, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 28403410, rs112563513 is associated with Metabolism/PK outcomes for caffeine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 28403410 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 28403410 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding rs112563513 and its association with metabolism or pharmacokinetic outcomes for caffeine."}]}
{"chain_id": "chain_000043", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20679962", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20679962, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with increased risk of side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that the *IMPDH II* rs11706052 (allele C) was not significantly associated with an increased risk of side effects or acute rejection when treated with mycophenolate mofetil."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs4974081 and mycophenolate mofetil in Disease:Kidney Transplantation (PMID 20679962)?", "answer": 456, "response": "The study included 456 cases for the analysis of rs4974081 and mycophenolate mofetil in kidney transplantation."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27182616", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27182616, is the following pharmacogenomic claim supported or contradicted: CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C9*1, CYP2C9*2 and warfarin in Dosage (PMID 27182616), what p-value was reported for this association?", "answer": "= 0.193", "response": "The p-value reported for the association between the mean daily ideal warfarin dose in patients with the wild-type CYP2C9*2 allele and the mean daily administered dose was <0.001."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28814798", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28814798, is the following pharmacogenomic claim supported or contradicted: Genotype CC is associated with decreased risk of Myelosuppression when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study indicates that the *LINC-PINT* rs1059698 CC genotype is associated with a protective effect against myelosuppression (OR = 0.407, 95%CI = 0.180\u20130.920, P = 0.031), suggesting that CC is associated with a decreased risk of myelosuppression compared to other genotypes, including AA + AC."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1059698 and Platinum compounds, radiotherapy in Disease:Nasopharyngeal Neoplasms (PMID 28814798), what OR was reported?", "answer": "0.395", "response": "The odds ratio (OR) reported for the *LINC-PINT* rs1059698 genotype in relation to myelosuppression when treated with Platinum compounds and radiotherapy in nasopharyngeal neoplasms was 0.407 (95%CI = 0.180\u20130.920, P = 0.031)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95%CI = 0.180\u20130.920) does not include the null value of 1.0."}]}
{"chain_id": "chain_000046", "chain_family": "B_claim\u2192presence_absence", "pmid": "22450926", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22450926, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 22450926, rs11702425 is associated with Metabolism/PK outcomes for methotrexate. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 22450926 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 22450926 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs11702425 being associated with Metabolism/PK outcomes for methotrexate."}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28049362", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28049362, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with Blood Coagulation Disorders when treated with warfarin as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study does not indicate any significant association between the allele T (specifically referring to the EPHX1 c.337T>C polymorphism) and blood coagulation disorders when treated with warfarin, as it was found to have nonsignificant association with dose requirement and risk of overanticoagulation."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs699664 and warfarin in Efficacy, Toxicity (PMID 28049362), what p-value was reported for this association?", "answer": "= 0.5110", "response": "The p-value reported for the association of rs699664 (GGCX 8016G>A) with warfarin efficacy and toxicity was not significant, as indicated by a p-value of .5110."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that allele A (rs1799971-A) was not significantly associated with heroin addiction risk when analyzed alone, while allele C (rs3778150-C) was associated with increased risk. Therefore, the statement that allele A is not associated with risk of Heroin Dependence compared to allele C is supported by the findings of the research."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10485060 and heroin in Toxicity (PMID 25744370), what p-value was reported for this association?", "answer": "= 0.23", "response": "The reported p-value for the association of rs10485060 with heroin addiction in the study was 0.34."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False. The p-value of 0.34 is not statistically significant at alpha = 0.05."}]}
{"chain_id": "chain_000049", "chain_family": "B_claim\u2192presence_absence", "pmid": "29027195", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29027195, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 29027195, rs3828743 is associated with Dosage, Other outcomes for abiraterone, prednisolone. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 29027195 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 29027195 reports a p-value of 0.013 for the association of the TSPYL1 rs3828743 SNP variant allele (A) with worse response to abiraterone, and an odds ratio (OR) of 2.47 (1.23, 4.96) for nonresponders. Additionally, a hazard ratio (HR) of 3.36 (95% confidence interval (CI): 1.34\u20138.40; p = 0.01) is reported for progression-free survival (PFS) in patients with the AA genotype compared to the GG genotype."}]}
{"chain_id": "chain_000050", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "19016697", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 19016697, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to methotrexate in people with Psoriasis as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2372536 and methotrexate in Disease:Psoriasis (PMID 19016697)?", "answer": 330, "response": "The study included 374 patients with psoriasis."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000051", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23963147", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23963147, is the following pharmacogenomic claim supported or contradicted: UGT1A1 *28 is not associated with response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of UGT1A1*28 and irinotecan, oxaliplatin, tegafur / gimeracil / oteracil in Disease:Colorectal Neoplasms (PMID 23963147)?", "answer": 42, "response": "The study included 42 patients who received the treatment, and all were genotyped for UGT1A1*28 among other polymorphisms."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000052", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22824134", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22824134, is the following pharmacogenomic claim supported or contradicted: Genotype AA is associated with decreased risk of Drug Hypersensitivity when treated with sulfamethoxazole in people with HIV Infections as compared to genotypes AC + CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study identifies SNP rs761142 in GCLC, where carriers of the minor G allele (GT and GG genotypes) are at increased risk of developing sulfamethoxazole-induced hypersensitivity, while the TT genotype (not AA) is associated with a lower risk. Therefore, the claim regarding genotype AA being associated with decreased risk is not supported by the findings of the study."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs761142 and sulfamethoxazole in Disease:HIV infectious disease (PMID 22824134), what OR was reported?", "answer": "2.2", "response": "The odds ratios (OR) reported for SNP rs761142 in the study are as follows: \n\n- For heterozygous carriers (GT vs TT), the odds ratio is 2.2 (95% confidence limits: 1.4 \u2013 3.7).\n- For homozygous carriers (GG vs TT), the odds ratio is 3.3 (95% confidence limits: 1.6 \u2013 6.8). \n\nAdditionally, each copy of the minor G allele was associated with a 1.9 fold increase in risk (OR = 1.9, 95% confidence limits: 1.4 \u2013 2.6)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence intervals for both reported odds ratios (2.2 and 3.3) do not include the null value of 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000053", "chain_family": "B_claim\u2192presence_absence", "pmid": "34476898", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34476898, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 34476898, CYP2A6 low activity is associated with Metabolism/PK outcomes for nicotine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 34476898 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 34476898 reports quantitative statistics, including p-values for the association of rare coding variants with decreased nicotine metabolite ratio (NMR) relative to the reference group. Specifically, it mentions statistical significance with p-values such as p < 0.001 and p < 0.0001 for the associations observed."}]}
{"chain_id": "chain_000054", "chain_family": "B_claim\u2192presence_absence", "pmid": "24192532", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24192532, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 24192532, rs2942857 is associated with Metabolism/PK outcomes for nicotine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 24192532 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 24192532 does not report any quantitative statistic (p-value, odds ratio, or confidence interval) for the claim regarding rs2942857."}]}
{"chain_id": "chain_000055", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28376280", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28376280, is the following pharmacogenomic claim supported or contradicted: Allele del is associated with increased response to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study indicates that carriers of the OPRM1 *G allele (which includes the G allele mentioned) have different subjective responses to alcohol compared to other genotypes, but it does not support the assertion that \"allele del\" (which is not specified in the paper) is associated with increased response to ethanol. The findings highlight the interactions between OPRM1 and DAT1 genotypes rather than supporting a direct association of \"allele del\" with increased ethanol response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs28363170 and ethanol in Other (PMID 28376280), what p-value was reported for this association?", "answer": "= 0.007", "response": "The reported p-value for the association of rs28363170 (DAT1 genotype) with the number of drinking days was p = <0.001."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000056", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29791014", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29791014, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found that the ABCG2 421C>A polymorphism (specifically the variant allele A) was associated with lower lamotrigine troughs in lamotrigine-only patients and higher troughs in lamotrigine + valproate patients, but it did not support the idea that allele T (which corresponds to the UGT1A4*3 142T>G polymorphism) is associated with increased concentrations of lamotrigine compared to allele G."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and lamotrigine in Disease:Epilepsy (PMID 29791014), what p-value was reported for this association?", "answer": "< 0.006", "response": "The p-value reported for the association between the ABCG2 421C>A polymorphism (rs2231142) and lamotrigine disposition was significant, with a p-value for the treatment\u2013genotype interaction being less than 0.0125."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000057", "chain_family": "B_claim\u2192presence_absence", "pmid": "18424454", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18424454, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 18424454, rs3789243 is associated with Dosage, Efficacy, Toxicity outcomes for methadone. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 18424454 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 18424454 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs3789243 and its association with dosage, efficacy, or toxicity outcomes for methadone."}]}
{"chain_id": "chain_000058", "chain_family": "B_claim\u2192presence_absence", "pmid": "39468242", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 39468242, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 39468242, rs4148325 is associated with Toxicity, Metabolism/PK outcomes for . Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 39468242 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 39468242 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding rs4148325 being associated with Toxicity, Metabolism/PK outcomes."}]}
{"chain_id": "chain_000059", "chain_family": "B_claim\u2192presence_absence", "pmid": "29923122", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29923122, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 29923122, rs116855232 is associated with Toxicity outcomes for mercaptopurine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 29923122 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 29923122 reports quantitative statistics for the claim, including p-values and odds ratios (OR). For example, it states a p-value of 2.20E\u221263 and an OR of 6.59 for the association of NUDT15 p.Arg139Cys with leukopenia."}]}
{"chain_id": "chain_000060", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29871907", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29871907, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased risk of Hypertension due to bevacizumab in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs6929249 and bevacizumab in Disease:Colorectal Neoplasms (PMID 29871907), what confidence interval was reported?", "answer": "5.8\u2013247.0", "response": "The confidence interval reported for rs6929249 was 95% CI: (5.8\u2013247)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000061", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "38004528", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 38004528, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT is associated with increased severity of hand-foot syndrome or Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found that the CES1 rs71647871-A allele (not CT + TT) was associated with an increased risk of severe hand-foot syndrome (HFS) and overall toxicity in patients treated with capecitabine. There is no mention of the CT + TT genotypes being associated with increased severity of HFS or drug toxicity compared to CC."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs71647871 and capecitabine in Other:Colorectal Neoplasms (PMID 38004528)?", "answer": 161, "response": "The study included 161 cases in the analysis of rs71647871 and capecitabine in colorectal neoplasms."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000062", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23776391", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23776391, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **supported**. The study found that post-menopausal women with the homozygous *CYP2D6*10/*10 genotype had significantly shorter disease-free survival compared to those with heterozygous (*CT*) or homozygous wild type (*CC*) genotypes at nucleotides 100C>T and 1039C>T, indicating an association with decreased event-free survival when treated with tamoxifen."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2D6*1, CYP2D6*10 and antineoplastic agents, tamoxifen in Disease:Breast Neoplasms (PMID 23776391)?", "answer": 16, "response": "The study included **57 cases** of breast cancer patients."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "**True.** The study meets the dataset minimum of N \u2265 30 for study cases, as it included 57 cases."}]}
{"chain_id": "chain_000063", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26914831", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26914831, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased severity of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted. The study focuses on the ABCG2 421C>A (Q141K) variant, not allele T or G, and finds that the A allele is associated with increased severity of thrombocytopenia in patients treated with sunitinib."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and sunitinib in Disease:Renal Cell Carcinoma (PMID 26914831), what confidence interval was reported?", "answer": "1.172\u20132.939", "response": "The reported confidence interval for the association of rs2231142 (ABCG2 421C>A) with severe thrombocytopenia was 95% CI = 1.17\u20132.94."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI = 1.17\u20132.94) does not include the null value of 1.0."}]}
{"chain_id": "chain_000064", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20590587", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20590587, is the following pharmacogenomic claim supported or contradicted: CYP2D6 poor metabolizer is associated with decreased concentrations of noroxymorphone in healthy individuals as compared to CYP2D6 ultrarapid metabolizer. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6 poor metabolizer genotype and noroxymorphone in Metabolism/PK (PMID 20590587), what p-value was reported for this association?", "answer": "= 2.8E-5", "response": "The p-value reported for the association between CYP2D6 poor metabolizer genotype and noroxymorphone concentrations was less than 0.0001."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000065", "chain_family": "B_claim\u2192presence_absence", "pmid": "26426352", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26426352, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26426352, rs200346442 is associated with Metabolism/PK outcomes for clopidogrel. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26426352 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 26426352 does not report any quantitative statistic (p-value, odds ratio, or confidence interval) for the claim regarding rs200346442 and its association with metabolism/pharmacokinetic outcomes for clopidogrel."}]}
{"chain_id": "chain_000066", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21882181", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21882181, is the following pharmacogenomic claim supported or contradicted: Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found that the combination of VEGF SNP 936 CC and VEGFR2 SNP 889 GG genotypes was associated with poorer overall survival, not the CC genotype alone."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2305948 and sunitinib in Disease:Renal Cell Carcinoma (PMID 21882181)?", "answer": 63, "response": "The study included 63 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000067", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18455228", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18455228, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Osteoporosis as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4355801 (PMID 18455228), what OR was reported?", "answer": "1.2", "response": "The odds ratio (OR) reported for rs4355801 in relation to osteoporosis was 1.2 (95% CI 1.01\u20131.42, p=0.038)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000068", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25710119", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25710119, is the following pharmacogenomic claim supported or contradicted: SLC6A4 L allele-rs25531T is not associated with response to milnacipran in people with Depressive Disorder, Major as compared to SLC6A4 L allele-rs25531C/L allele-rs25531C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study indicates that the SLC6A4 L allele in combination with rs25531 does not show a significant association with the response to milnacipran, as the genetic variants influencing milnacipran response were identified as HTR-1A-1019C/G and ADRA2A-1297C/G, not SLC6A4."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T and milnacipran in Other:Major Depressive Disorder (PMID 25710119)?", "answer": 42, "response": "The study included 45 cases for the milnacipran sample, which would encompass the analysis of SLC6A4 L allele-rs25531C and SLC6A4 L allele-rs25531T in patients with Major Depressive Disorder."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000069", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26261165", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26261165, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with response to escitalopram Depressive Disorder, Major as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no significant association between the SNPs analyzed and response to escitalopram in patients with Major Depressive Disorder, indicating that allele T is not associated with treatment response compared to allele C."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs6311 and escitalopram in Other:Major Depressive Disorder (PMID 26261165)?", "answer": 55, "response": "The study included 55 cases for the analysis of rs6311 and escitalopram in patients with Major Depressive Disorder."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True. The study meets the dataset minimum of N \u2265 30 for study cases, as it included 55 cases."}]}
{"chain_id": "chain_000070", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23691226", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23691226, is the following pharmacogenomic claim supported or contradicted: Genotypes AA + AG is associated with increased dose of acenocoumarol as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that genotype AA (rs17878544) requires a slightly lower acenocoumarol dose compared to genotype GG, while genotype AG is associated with a higher dose requirement."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs7200749 and acenocoumarol in Dosage (PMID 23691226)?", "answer": 3949, "response": "The study included 3949 consecutive patients taking acenocoumarol for the analysis of rs7200749 and its association with acenocoumarol dosage."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000071", "chain_family": "B_claim\u2192presence_absence", "pmid": "32606912", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32606912, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 32606912, rs1800872 is associated with Dosage outcomes for sufentanil. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 32606912 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 32606912 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs1800872 and its association with dosage outcomes for sufentanil."}]}
{"chain_id": "chain_000072", "chain_family": "B_claim\u2192presence_absence", "pmid": "27597944", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27597944, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 27597944, HLA-DQB1*02:01 is associated with Toxicity outcomes for nevirapine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 27597944 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 27597944 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding HLA-DQB1*02:01 being associated with toxicity outcomes for nevirapine. The study focuses on HLA-DQB1*02:01 and HLA-DQA1*01:02 in relation to antituberculosis drug-induced hepatotoxicity, not nevirapine."}]}
{"chain_id": "chain_000073", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18322281", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18322281, is the following pharmacogenomic claim supported or contradicted: Genotypes AA + AG is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that patients with the A/A haplotype of VKORC1 had a decreased time to the first INR within the therapeutic range compared to those with the non-A/non-A haplotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2359612 and warfarin in Efficacy (PMID 18322281), what confidence interval was reported?", "answer": "1.06\u20131.92", "response": "The study reported a confidence interval of 95% for the hazard ratios associated with the outcomes, specifically for the VKORC1 variants. However, the exact confidence interval values for rs2359612 are not explicitly stated in the provided text. The reported hazard ratios and their confidence intervals are generally presented in Table 4 of the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence intervals for the hazard ratios (HR) reported in the study do not include the null value of 1.0, indicating a statistically significant association."}]}
{"chain_id": "chain_000074", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28525903", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28525903, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found no significant association between the SLC19A1 rs2838958 genotypes (AG + GG) and methotrexate concentrations compared to the AA genotype, as indicated by the P-value of 0.259 in the results."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2838958 and methotrexate in Disease:Acute lymphoblastic leukemia (PMID 28525903)?", "answer": 317, "response": "The study included 322 cases of children with acute lymphoblastic leukemia (ALL)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000075", "chain_family": "B_claim\u2192presence_absence", "pmid": "31493434", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31493434, is the following pharmacogenomic claim supported, contradicted, or not reported: Allele T is not associated with response to heroin as compared to allele C. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 31493434 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 31493434 does not report any quantitative statistic (p-value, odds ratio, or confidence interval) specifically for the claim regarding the association of allele T with response to heroin compared to allele C."}]}
{"chain_id": "chain_000076", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27005817", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27005817, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs13431554 and aspirin, clopidogrel in \"Disease:Coronary Artery Disease\", \"Disease:Diabetes Mellitus, Type 2\" (PMID 27005817)?", "answer": 674, "response": "A total of 674 cases were included in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000077", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "19659438", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 19659438, is the following pharmacogenomic claim supported or contradicted: Allele C (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele T (assigned as normal metabolizer phenotype) . Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that certain polymorphisms in CYP2B6, including those associated with the poor metabolizer phenotype, are linked to decreased plasma efavirenz concentrations, suggesting reduced metabolism of efavirenz in individuals with these alleles."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs28399499 and efavirenz in Disease:HIV infectious disease (PMID 19659438)?", "answer": 45, "response": "The study included 45 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000078", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "30723321", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 30723321, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased response to migalastat in people with Fabry Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **not supported**. The paper does not provide evidence that any specific allele, including allele C, is associated with an increased response to migalastat in people with Fabry disease. The study focuses on the efficacy of migalastat in patients with amenable GLA variants but does not link specific alleles to treatment response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**. The study evaluates the clinical outcomes of patients with Fabry disease receiving migalastat, focusing on their phenotypes and treatment responses, which is indicative of clinical associations rather than functional assays."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs398123226 and migalastat in Other:Fabry Disease (PMID 30723321)?", "answer": 50, "response": "The study included **36 cases** in the \"Other\" subgroup, which consisted of males not meeting classic phenotype criteria and all females with Fabry disease."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "**True.** The dataset meets the minimum of N \u2265 30 for study cases, as it includes 36 cases in the \"Other\" subgroup."}]}
{"chain_id": "chain_000079", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "31721892", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31721892, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are associated with decreased response to escitalopram in people with Depression as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study did not find any significant association between the genotypes (including GT + TT) and the response to escitalopram in patients with depression."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1800532 and escitalopram in Other:Depression (PMID 31721892), what p-value was reported for this association?", "answer": "= 0.038", "response": "The p-value reported for the association between rs1800532 (TPH1) and escitalopram was 0.33."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False."}]}
{"chain_id": "chain_000080", "chain_family": "B_claim\u2192presence_absence", "pmid": "28045923", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28045923, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 28045923, rs11989215 is associated with Efficacy outcomes for bevacizumab. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 28045923 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 28045923 does not report any quantitative statistic (p-value, odds ratio, or confidence interval) for the claim regarding rs11989215."}]}
{"chain_id": "chain_000081", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "31461080", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31461080, is the following pharmacogenomic claim supported or contradicted: CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that low-intermediate/poor metabolizer genotypes (which include *1/*3, *2/*2, *2/*3, and *3/*3) were associated with increased dose-adjusted phenytoin blood concentrations and an increased risk of neurological side effects compared to extensive metabolizers (*1/*1)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C9*1, CYP2C9*2, CYP2C9*3 and phenytoin in Toxicity (PMID 31461080), what HR was reported?", "answer": "2.4", "response": "The hazard ratio (HR) reported for low-intermediate/poor metabolizers compared to extensive metabolizers regarding the risk of neurological side effects was 2.40 (95% CI: 1.24 \u2013 4.64; p < 0.01)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval (95% CI: 1.24 \u2013 4.64) does not include the null value of 1.0."}]}
{"chain_id": "chain_000082", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20128861", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20128861, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with dose of warfarin as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim \"Allele C is not associated with dose of warfarin as compared to allele G\" is supported. The study found that warfarin doses did not significantly vary according to the genotype of *CYP4F2*, *CALU*, or *GGCX*, which includes allele C and G comparisons."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs11676382 and warfarin in Dosage (PMID 20128861)?", "answer": 145, "response": "The study included a total of 145 cases for the analysis of warfarin dosing, but the specific number of cases for the variant rs11676382 (GGCX) is not explicitly stated in the provided information. However, it mentions that the inclusion of rs11676382 did not enhance algorithm performance, indicating that the number of subjects with this variant was likely small."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "False. The specific number of cases for rs11676382 is not provided, but it is implied that the number was small, likely below the minimum of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000083", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24590654", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24590654, is the following pharmacogenomic claim supported or contradicted: Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Diarrhea, Drug Toxicity or hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study found no good evidence of association between the polymorphisms analyzed and toxicity in patients treated with capecitabine, including diarrhea and hand-foot syndrome. The specific allele mentioned is not supported by the findings in the paper."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs45445694 and capecitabine in Disease:Colorectal Neoplasms (PMID 24590654), what OR was reported?", "answer": "1.44", "response": "The study reported an odds ratio (OR) of 1.27 for rs45445694 in relation to capecitabine toxicity in colorectal neoplasms."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "False. The confidence interval for the OR of 1.27 includes the null value of 1.0, indicating that the association is not statistically significant."}]}
{"chain_id": "chain_000084", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18433502", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18433502, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with response to ethanol as compared to allele G. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that endorsing a more intense response to alcohol was significantly associated with having at least one minor allele for several SNPs in the OPRM1 gene, and specifically noted that for the A118G allele (where G is the minor allele), there was only a trend for an association with reporting a less intense response to alcohol. Therefore, allele T (the major allele) is not associated with a more intense response compared to allele G."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs642489 and ethanol in Efficacy (PMID 18433502)?", "answer": 251, "response": "The study included 251 participants in total, but specific case numbers for the SNP rs642489 and its association with ethanol response are not detailed in the provided text. Therefore, the exact number of cases specifically for rs642489 cannot be determined from the information given."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True. The study included 251 participants, which exceeds the minimum dataset requirement of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000085", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28730340", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28730340, is the following pharmacogenomic claim supported or contradicted: CYP2D6 poor metabolizer is not associated with likelihood of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that CYP2D6 poor metabolizer status was not associated with recurrence-free survival in tamoxifen-treated patients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6 poor metabolizer and tamoxifen in Disease:Breast Neoplasms (PMID 28730340), what confidence interval was reported?", "answer": "0.33\u20131.4", "response": "The confidence interval reported for the association between increasing CYP2D6 activity score and inferior recurrence-free survival in tamoxifen-treated patients was 95% confidence interval: 1.00\u20132.04."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False. The confidence interval for the HR (1.00\u20132.04) includes the null value of 1.0."}]}
{"chain_id": "chain_000086", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "34158603", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34158603, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study identifies several genetic variants associated with major adverse cardiovascular events (MACE) in patients treated with clopidogrel and aspirin, including specific SNPs where certain alleles are linked to increased risk. For example, the variant rs17064642 in the MYOM2 gene (allele C) is associated with a higher occurrence of MACE compared to non-carriers. However, the specific alleles A and G are not mentioned in the provided data, so the claim cannot be definitively confirmed without additional context regarding those specific alleles. Therefore, based on the information provided, the claim is **contradicted** as it does not directly reference the alleles A and G."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**. The study identifies genetic variants associated with major adverse cardiovascular events (MACE) in patients treated with clopidogrel and aspirin, indicating a clinical correlation between specific genotypes and patient outcomes."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3749187 and aspirin, clopidogrel in Other:Acute coronary syndrome (PMID 34158603), what p-value was reported for this association?", "answer": "= 3.37E-5", "response": "The reported p-value for the association of rs3749187 (ZDHHC3) with major adverse cardiovascular events (MACE) in patients treated with aspirin and clopidogrel was **4.12 \u00d7 10^\u22122** in the discovery cohort and **3.37 \u00d7 10^\u22125** in the replication cohort."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "**False.** The p-value of 4.12 \u00d7 10^\u22122 (0.0412) is greater than 0.01, indicating that the association would not remain significant at an alpha level of 0.01."}]}
{"chain_id": "chain_000087", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27114598", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27114598, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The paper identifies a rare nonsense variant rs199695765 in the CPA2 gene, which is associated with a significantly increased risk of asparaginase-induced pancreatitis. The variant is a T allele, indicating that individuals carrying this allele have a markedly higher risk compared to those with the C allele."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs199695765 and asparaginase in Disease:Acute lymphoblastic leukemia (PMID 27114598)?", "answer": 3256, "response": "The study included 2 cases of rs199695765 in the cohort of patients with acute lymphoblastic leukemia."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "False."}]}
{"chain_id": "chain_000088", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26098993", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26098993, is the following pharmacogenomic claim supported or contradicted: Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study found that the favorable *IFNL4* genotype CC is associated with an increased sustained virological response (SVR) to peginterferon therapy in individuals with Hepatitis C, compared to those with genotypes CT and TT."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs12979860 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMID 26098993), what p-value was reported for this association?", "answer": "= 0.008", "response": "The p-value reported for the association between the favorable *IFNL4* genotype CC and increased sustained virological response (SVR) was 0.021."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "False. The p-value of 0.021 is greater than the alpha level of 0.01, indicating that the association would not remain significant at that threshold."}]}
{"chain_id": "chain_000089", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "21801394", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 21801394, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3094188 and allopurinol in Toxicity (PMID 21801394), what OR was reported?", "answer": "7.77", "response": "The odds ratio (OR) reported for rs3094188 in association with allopurinol-induced Toxic Epidermal Necrolysis (TEN) was 1.59 (95% CI = [1.34; 1.88])."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000090", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "34464454", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34464454, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are associated with increased response to cannabidiol in people with Epilepsy as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The study indicates that patients with the AOX1 rs6729738 CC genotype are more likely to respond to cannabidiol, while the CT + TT genotypes would not be associated with increased response."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs12539 and cannabidiol in Other:Epilepsy (PMID 34464454)?", "answer": 112, "response": "A total of 112 cases were included in the study of rs12539 and cannabidiol in the context of epilepsy (PMID 34464454)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True. The dataset meets the minimum of N \u2265 30 for study cases."}]}
{"chain_id": "chain_000091", "chain_family": "B_claim\u2192presence_absence", "pmid": "25148458", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25148458, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 25148458, rs117996576 is associated with Metabolism/PK outcomes for anastrozole, exemestane. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 25148458 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 25148458 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) for the claim regarding rs117996576 being associated with metabolism or pharmacokinetic outcomes for anastrozole or exemestane."}]}
{"chain_id": "chain_000092", "chain_family": "B_claim\u2192presence_absence", "pmid": "23213055", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23213055, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 23213055, CYP2D6*1, CYP2D6*3, CYP2D6*4 is associated with Dosage, Efficacy, Toxicity, Metabolism/PK outcomes for tamoxifen. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 23213055 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 23213055 does not report any quantitative statistics (p-value, odds ratio, or confidence interval) specifically for the claim regarding CYP2D6*1, CYP2D6*3, and CYP2D6*4 being associated with dosage, efficacy, toxicity, or metabolism/PK outcomes for tamoxifen. The study primarily focuses on the association of CYP2D6 genotypes with disease events during tamoxifen treatment, specifically mentioning poor metabolizers (PM) and extensive metabolizers (EM) but does not provide statistics for the specific alleles mentioned in the claim."}]}
{"chain_id": "chain_000093", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "34871222", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34871222, is the following pharmacogenomic claim supported or contradicted: Genotypes AA + AC are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **supported**. The study found no significant differences in the incidence of Constipation, Delirium, Nausea, Pruritus, or Urinary Retention between the AA + AC genotypes and the CC genotype for the relevant SNPs. Additionally, the only significant finding related to somnolence was for the OPRM1 and COMT variants, which did not include the AA + AC genotypes in relation to constipation or other adverse effects."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**. The study investigates the relationship between genetic variants and the incidence of adverse effects in patients treated with opioids, which is a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs324420 and morphine, oxycodone in Other:Lung Neoplasms (PMID 34871222), what OR was reported?", "answer": "0.7", "response": "For the study of rs324420 and morphine or oxycodone in patients with lung neoplasms, no significant odds ratio (OR) was reported for the association with adverse effects. The study indicated that while AA carriers for rs1045642 had a higher incidence of nausea compared with carriers of other alleles (OR, 2.6; 95% CI, 0.9\u20137.7), there was no significant finding for rs324420. Therefore, the specific OR for rs324420 was not provided in the context of the adverse effects studied."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "**False.** The confidence interval for the OR reported for rs324420 does not exclude the null value of 1.0, indicating that the association was not statistically significant."}]}
{"chain_id": "chain_000094", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "19365400", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 19365400, is the following pharmacogenomic claim supported or contradicted: CYP2A6 *1/*35 + *9/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35 and nicotine in Metabolism/PK (PMID 19365400)?", "answer": 284, "response": "The study included a total of 1,234 alleles from African American smokers for CYP2A6*1, and 617 individuals from the African American population were genotyped, but specific case numbers for CYP2A6*9, CYP2A6*17, and CYP2A6*35 are not explicitly stated in the provided text. Therefore, the total number of cases specifically analyzed for CYP2A6*1, *9, *17, and *35 in relation to nicotine metabolism is not clearly defined."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000095", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24060820", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24060820, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizer phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **contradicted**. The study found that CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS) in tamoxifen-treated patients when strict eligibility criteria were applied."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11 and tamoxifen in Disease:Breast Neoplasms (PMID 24060820), what HR was reported?", "answer": "1.07", "response": "For the study of CYP2D6*4 and tamoxifen in breast neoplasms, a hazard ratio (HR) of 1.25 was reported for invasive disease-free survival (IDFS) when strict eligibility criteria were applied. The HR for breast cancer-free interval was 1.27."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True. The confidence intervals for both HRs (1.25 with a 95% confidence interval of 1.06 to 1.47 for IDFS and 1.27 with a 95% confidence interval of 1.01 to 1.61 for breast cancer-free interval) do not include the null value of 1.0."}]}
{"chain_id": "chain_000096", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "16476706", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 16476706, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of Alcoholism or Cocaine-Related Disorders due to cocaine or ethanol as compared to allele C. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is supported. The study found that the minor allele (C-allele) of SNP5 (rs495491) was associated with increased risk for alcohol dependence (AD) and drug dependence (DD), while the T-allele of SNP11 (which is not the focus of the claim) was associated with a protective effect against AD and DD. Therefore, allele T is not associated with increased risk compared to allele C."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs548646 and cocaine, ethanol in Toxicity (PMID 16476706), what p-value was reported for this association?", "answer": "= 0.576", "response": "The study did not report a specific p-value for the association of rs548646 (SNP9) with cocaine or ethanol in the context of toxicity. The focus of the reported p-values was primarily on SNPs 4, 5, 11, and 12 in relation to alcohol dependence and drug dependence. Therefore, no p-value for rs548646 in this context is provided in the paper."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False. The study did not report a specific p-value for rs548646, and therefore, we cannot determine if it is statistically significant at alpha = 0.05."}]}
{"chain_id": "chain_000097", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40184070", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40184070, is the following pharmacogenomic claim supported or contradicted: CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) . Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported. The study indicates that carriers of the loss-of-function CYP2C19 alleles (intermediate and poor metabolizers) have a higher likelihood of experiencing cardiovascular events, including stroke, myocardial infarction, or death, when treated with clopidogrel compared to noncarriers (normal metabolizers)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17 and clopidogrel in Other:Stroke (PMID 40184070)?", "answer": 2910, "response": "The study included a total of 2910 cases."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000098", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "36614097", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 36614097, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with clinical benefit to aspirin, diclofenac, ibuprofen, indomethacin, ketorolac or naproxen in people with Migraine without Aura as compared to allele A. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "The claim is **contradicted**. The study found that the A allele of the TNF-\u03b1 promoter (\u2212308 A/G) is associated with a lack of efficacy after NSAID administration, indicating that allele G is associated with a better clinical response to NSAIDs like aspirin, diclofenac, ibuprofen, indomethacin, ketorolac, or naproxen in people with Migraine without Aura."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs16944 and aspirin, diclofenac, ibuprofen, indomethacin, ketorolac, naproxen in Other:Migraine without Aura (PMID 36614097)?", "answer": 65, "response": "The study included **313 cases** for the analysis of rs16944 and the response to NSAIDs (aspirin, diclofenac, ibuprofen, indomethacin, ketorolac, and naproxen) in patients with Migraine without Aura."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000099", "chain_family": "B_claim\u2192presence_absence", "pmid": "26030142", "num_turns": 2, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26030142, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26030142, rs35684750 is associated with Efficacy, Toxicity, Other outcomes for vancomycin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Not_reported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26030142 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 26030142 does not report any quantitative statistic (p-value/OR/CI) for the claim regarding rs35684750, as this specific SNP is not mentioned in the paper. The study primarily discusses the SNP rs2789047 and its associated statistics."}]}
